DE3576690D1 - Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel. - Google Patents

Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel.

Info

Publication number
DE3576690D1
DE3576690D1 DE8585810182T DE3576690T DE3576690D1 DE 3576690 D1 DE3576690 D1 DE 3576690D1 DE 8585810182 T DE8585810182 T DE 8585810182T DE 3576690 T DE3576690 T DE 3576690T DE 3576690 D1 DE3576690 D1 DE 3576690D1
Authority
DE
Germany
Prior art keywords
sub
alkyl
production
pharmaceutical preparations
preparations containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8585810182T
Other languages
German (de)
English (en)
Inventor
Norihiko Inst Of Bio- Kitamura
Akimoto Nippon Zoki Ph Ohnishi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3576690D1 publication Critical patent/DE3576690D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE8585810182T 1984-04-24 1985-04-24 Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel. Expired - Fee Related DE3576690D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP59083557A JPS60226882A (ja) 1984-04-24 1984-04-24 新規ピリミドピリミジン誘導体

Publications (1)

Publication Number Publication Date
DE3576690D1 true DE3576690D1 (de) 1990-04-26

Family

ID=13805812

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8585810182T Expired - Fee Related DE3576690D1 (de) 1984-04-24 1985-04-24 Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel.

Country Status (5)

Country Link
US (1) US4886807A (enExample)
EP (1) EP0163599B1 (enExample)
JP (1) JPS60226882A (enExample)
AT (1) ATE51231T1 (enExample)
DE (1) DE3576690D1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928346D0 (en) * 1989-12-15 1990-02-21 Smith Kline French Lab Chemical compounds
TW517055B (en) * 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
AU8389498A (en) * 1997-07-11 1999-02-08 Eli Lilly And Company Combinatorial process for preparing fused substituted pyrimidine libraries
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US20040044012A1 (en) * 1998-05-26 2004-03-04 Dobrusin Ellen Myra Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
GEP20033093B (en) 1998-05-26 2003-10-27 Warner Lambert Co Bicyclic Pyrimidines and Bicyclic 3,4-Dihydropyrimidines as Inhibitors of Cellular Proliferation, Compositions Containing Them and Methods for Treating Cell Proliferative Disorders
DE69917296T2 (de) 1998-08-20 2005-05-25 Smithkline Beecham Corp. Neue substituierte triazolverbindungen
JP2000119272A (ja) * 1998-10-15 2000-04-25 Nippon Zoki Pharmaceut Co Ltd 新規７−アミノピリド〔２，３−ｄ〕ピリミジン誘導体
US6548503B1 (en) 1998-11-04 2003-04-15 Smithkline Beecham Corporation Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
ES2241675T3 (es) 1999-11-23 2005-11-01 Smithkline Beecham Corporation Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de cspb/p38 quinasa.
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
ES2230171T3 (es) 1999-11-23 2005-05-01 Smithkline Beecham Corporation Compuestos 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p38 quinasa.
MY141144A (en) * 2000-03-02 2010-03-15 Smithkline Beecham Corp 1, 5-disubstituted-3,4-dihydro-1h-pyrimido 4,5-dipyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
US7235551B2 (en) * 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
TWI243055B (en) 2000-04-13 2005-11-11 Nippon Zoki Pharmaceutical Co Pharmaceutical composition for use in treatment of dermatitis
PT1333833E (pt) * 2000-10-23 2011-12-09 Glaxosmithkline Llc Novo composto 8h-pirido[2,3-d]pirimidin-7-ona trissusbtituída para o tratamento de doenças mediadas por csbp/p38 cinase
US7629350B2 (en) * 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
PA8577501A1 (es) * 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7084270B2 (en) * 2002-08-14 2006-08-01 Hoffman-La Roche Inc. Pyrimido compounds having antiproliferative activity
US7112676B2 (en) * 2002-11-04 2006-09-26 Hoffmann-La Roche Inc. Pyrimido compounds having antiproliferative activity
RU2350617C2 (ru) * 2003-04-10 2009-03-27 Ф.Хоффманн-Ля Рош Аг Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр
ZA200601859B (en) * 2003-08-05 2008-03-26 Vertex Pharma Condensed pyrimidine compounds as inhibitors of voltagegated ion channels
US7423042B2 (en) * 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
EP1865959A2 (en) * 2005-03-25 2007-12-19 Glaxo Group Limited Process for preparing pyridoý2,3-d¨pyrimidin-7-one and 3,4-dihydropyrimidoý4,5-d¨pyrimidin-2(1h)-one derivatives
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
PE20061193A1 (es) * 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US8006342B2 (en) 2007-04-12 2011-08-30 Dr. Fresh, Inc. Illuminated flashing toothbrush and method of use
CN102816162B (zh) * 2011-06-10 2016-04-27 中国科学院广州生物医药与健康研究院 嘧啶并嘧啶酮类化合物及其药用组合物和应用
US9044083B2 (en) 2012-08-15 2015-06-02 Children Oral Care, Llc Illuminated multi-light flashing toothbrush and method of use
CN104418860B (zh) * 2013-08-20 2016-09-07 中国科学院广州生物医药与健康研究院 嘧啶并杂环类化合物及其药用组合物和应用
US20220274991A1 (en) * 2019-07-16 2022-09-01 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of ku70/80 and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4832899A (enExample) * 1971-08-28 1973-05-02
JPS5826757B2 (ja) * 1975-04-15 1983-06-04 ヒサミツセイヤク カブシキガイシヤ シンキナピリミド（４ ５−ｄ）ピリミジンユウドウタイノ セイゾウホウ
JPS5920675B2 (ja) * 1975-06-05 1984-05-15 久光製薬 （株） 新規なピリミド〔４，５−ｄ〕ピリミジン誘導体の製造法
JPS5920676B2 (ja) * 1975-06-05 1984-05-15 久光製薬 （株） 新規なピリミド〔４，５−ｄ〕ピリミジン誘導体の製造法
JPS5920677B2 (ja) * 1975-07-23 1984-05-15 久光製薬 （株） 新規なピリミド〔４、５−ｄ〕ピリミジンジオン誘導体の製造法

Also Published As

Publication number Publication date
US4886807A (en) 1989-12-12
EP0163599A2 (en) 1985-12-04
EP0163599A3 (en) 1987-02-25
JPS60226882A (ja) 1985-11-12
JPH0559118B2 (enExample) 1993-08-30
EP0163599B1 (en) 1990-03-21
ATE51231T1 (de) 1990-04-15

Similar Documents

Publication Publication Date Title
DE3576690D1 (de) Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel.
ATE150462T1 (de) Pyrazolopyridinverbindungen und verfahren zu ihrer herstellung
EP0482410A3 (en) Anti-microbial compounds, including substituted 2-cyclohexyl-amine derivatives and their preparation
DE69310602D1 (de) 3',5'-Ditertbutyl-4'-Hydroxyflavone, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzung mit Antioxidations- und Antivasokonstriktionsaktivität
HU9202044D0 (en) Method for producing 4-phenyl-piperidine-4-carbixamide derivatives and pharmaceutical preparatives containing these compounds as active agents
ATE10368T1 (de) Uracilderivate, verfahren zu ihrer herstellung und eine diese enthaltende pharmazeutische zubereitung.
DE69318238D1 (de) Benzopyran-Verbindungen, Verfahren zu ihrer Herstellung und ihre Verwendung als Zellenschutzmittel
AU656466B2 (en) New benzimidazole compounds, a process for their preparation and pharmaceutical compositions containing them
GR3024686T3 (en) Novel guinolone and naphthyridone derivatives.
IE872658L (en) Tetrahydroquinoline derivatives, a process for their preparation, their use and pharmaceutical formulations containing them
ATE25679T1 (de) Isochinolinderivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung.
MY132057A (en) Quinoxalinones, a process for their preparation and their use
EP0186023A3 (en) Biliary acid derivatives, process for their preparation and pharmaceutical compositions containing them
ATE21101T1 (de) N-iminopyridinium-betain-derivate, ihre herstellung und ihre verwendung als arzneimittel.
ATE53209T1 (de) Piperazinverbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung.
DE59109029D1 (de) 3-substituierte Cephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
ATE133177T1 (de) 3'-deamino-4'-deoxy-4'-amino-8-fluoranthracycli e und verfahren zu ihrer herstellung
ES550781A0 (es) Un procedimiento para preparar un derivado de 1-benzhidril--4-cinamilpiperazina
ES8304936A1 (es) Procedimiento de preparacion de un nuevo derivado de benzoilfenil-piperidina.
ES8401488A1 (es) Procedimiento de preparacion de derivados de diaza-3,7a-cicloherta-(j,k)-fluorenos.
DE69215511D1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen
DE3674250D1 (de) Phenylpyrazinderivate, verfahren zu deren herstellung, pharmazeutische zusammensetzung und verwendung.
ATE43586T1 (de) Arphameninderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
ATE112268T1 (de) 2-amino-1,2,3,4-tetrahydroisochinolin-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel.
DK0463139T3 (da) 2,13-disubstituerede ergoliner, deres fremstilling og deres anvendelse i lægemidler

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee